U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Partnerships: Enhancing Science Through Collaborations With FDA
  4. FDA Memoranda of Understanding
  5. Non-Profit and Other MOUs
  1. FDA Memoranda of Understanding

Non-Profit and Other MOUs

MOU No. Purpose Parties FDA Lead Center or
Office Contact
Effective Date Expiration Date Last Revision Date

225-24-002
To promote awareness and develop strategies to identify, mitigate, and prevent cybersecurity threats to medical devices. Health Information Sharing & Analysis Center, Inc. (Health-ISAC)

CDRH
Suzanne B. Schwartz, M.D., M.B.A.
(301) 796-6937

CDRH
Jessica Wilkerson, J.D.
(240) 401-8691
 

2023-12-14 2028-12-14  
225-22-018 Share interest in scientific progress in the disciplines that directly and indirectly affect human and animal health and medicine. Society of Toxicology Office of the Chief Scientist
Chad P. Nelson, Ph.D., M.S.P.H
301-796-4643
2022-07-29 2027-07-29  
225-20-015 The Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), the American Association for Cancer Research (AACR), Oncology Nursing Society (ONS) and Hematology/Oncology Pharmacy Association (HOPA) agree to collaborate in Project Livin’ Label, a new educational initiative aimed at increasing awareness of recent FDA oncology drug approvals and understanding of the associated drug product label. The FDA, AACR, ONS and HOPA share interests in promoting scientific progress through exchange of scientific capital in oncology education, collaborative learning, and research. All institutions foresee benefits from collaborating in this new educational initiative focused on regulatory policy. This Memorandum of Understanding (MOU) establishes the terms for the collaboration for Project Livin’ Label and provides a basis for other related efforts to promote these shared, mutual interests in collaborative education and learning. American Association for Cancer Research (AACR), Oncology Nursing Society (ONS) and Hematology/Oncology Pharmacy Association (HOPA) Oncology Center of Excellence
Laura B. Wisch
Program Manager for Education
10903 New Hampshire Ave, WO 22/2135
Silver Spring, MD 20993
Laura.wisch@fda.hhs.gov
301-538-6580
2022-05-03 2027-05-03  
225–20–018 FDA and the Academy will collaborate to increase the awareness of agricultural biotechnology/genetically engineered foods and develop educational materials for dietitians. Academy of Nutrition and Dietetics CFSAN
Sharmi Das
Phone: (240) 402-3786
2020-09-04 Lifespan of the CPE Learning Series (a maximum of 3 years)  
225-78-1000 States the responsibilities of the FDA and NCIMS for execution of the Interstate Milk Shippers Program, the means for resolving questions of interpretation that may arise in the execution of the Program, and the means for making modifications in the Program. National Conference on Interstate Milk Shipments CFSAN
Monica Metz
(240) 402-2041
1977-09-12 Indefinite  
225-83-3000 Defines the working arrangements between FDA and USPC in regards to the review revisions to compendial requirements for drugs. U.S. Pharmacopeial Convention, Inc. (USPC) CDER
Diane Ehrlich
(301) 443-5373
1983-09-07 Indefinite  
225-84-2003 To foster and improve the sanitation and quality of shellfish in the U.S. Interstate Shellfish Sanitation Conference (ISSC) CFSAN
Donald Kraemer
(240) 402-2300
1984-03-14 Indefinite  
225-93-4006 CFP and FDA agree to establish a working relationship to address issues on food safety in order to implement the recommendations adopted at Conference meetings. Conference for Food Protection (CFP) ORA
Diana Kolaitis
(718) 662-5416
1993-08-01 Indefinite  
225-93-7000 Evaluating test kits for detecting animal drug residues in milk. AOAC CVM
Tracey Forfa
(240) 276-9006
1992-10-22 Indefinite  
225-03-4000B FDA and NTEU agree to work together regarding mandatory foreign inspection assignments. National Treasury Employees Union (NTEU) ORA
Diana Kolaitis
(718) 662-5416
2003-06-11 expires w/contract  
225-04-4002 FDA and BIG will work together to address issues affecting children, families, and communities within each organizations jurisdiction through educational campaigns-food safety. Blacks in Government (BIG) OC
LaJuana Caldwell
(301) 827-4450
2003-10-22 Indefinite  
225-10-0021 Defines the framework in which the FDA will provide publicly available content to be used in health professional informational, educational, and training programs that will be run by WebMD LLC ("WebMD") and Medscape, LLC ("Medscape"), an entity accredited by ACCME, ANCC, and the ACPT to provide continuing professional education to physicians, nurses and pharmacists, respectively. Amended to extend expiration date. Medscape, LLC and WebMD OC/OEA
Anna Fine
(301) 796-8471
2014-06-07 2019-06-06  
225-11-0017 Defines the framework for collaboration between CDER and FDA and the Institute for Safe Medication Practices. The purpose of the collaboration is to improve the safety of the American public when using CDER-regulated products. Amendment 1 to extend timeframe. Amendment 2 to clarify point of contact for conveyance of information. Institute for Safe Medication Practices CDER
Cynthia Fitzpatrick
(301) 796-3115
2014-07-17 Indefinite  
225-11-0021 Establishes a strategic framework for collaboration between FDA and the Uppsala Monitoring Centre (UMC) in Sweden and outlines the process for collaborative sharing of public information between the FDA and the UMC for carrying out their common goal to improve the global safety and effective use of medicinal products. Uppsala Monitoring Centre (Sweden) CDER
Gerald Dal Pan
(301) 796-2380
2012-05-15 Indefinite  
225-12-0001 The purpose of MOU 225-12-0001 is to promote initiatives related to radiation protection from CT medical imaging. Heads of the European Radiological protection Competent Authorities (HERCA) CDRH 2012-02-02 Indefinite  
225-12-0038 Establishes the terms for collaboration to promote these shared interests education and research, and mutual exchange of training and research expertise in clinical pharmacology and translational science. American Society of Nephrology CDER
Patrick Archdeacon
(301) 796-3952
2012-09-06 Indefinite  
225-13-0027 Collaborate on developing new methods to evaluate the toxicity of substances regulated by the FDA; improving the pathway for the review and approval of regulated substances; facilitating the FDA’s engagement with scientists from academia, government and industry on regulatory science questions that impact drug development and safety prediction; sharing information that is in the public domain and considered non-confidential; and publicly disseminating scientific knowledge to help bring safe and effective products to market. ILSI Health and Evironmental Sciences Institute CDER 2013-09-12 Indefinite  
225-14-0006 Establish framework for collaboration between FDA and Washington Adventist Hospital including collaborative research, public outreach, extension activities, training, and exchange of medical professionals and staff by the two organizations. Washington Adventist Hospital Eileen Parish, M.D.
Office of the Chief Scientist
(301) 796-8522
2008-12-16 Indefinite  
225-14-0019 The FDA/CDRH and H-ISAC have a shared interest in encouraging the identification, mitigation, and prevention of cybersecurity threats to medical devices. The purpose of this collaboration is to establish a basis upon which to foster and improve the safety of medical devices from cybersecurity threats. The Health Information Sharing  & Analysis Center, INC (H-ISAC)

CDRH
Suzanne Schwartz
Deputy Director, OST
(301) 796-6937

2020-01-31 2025-01-30  
225-14-012 Collaborative health professional training, outreach, and research initiatives. American Nurses Association Teresa Rubio
(301) 796-5113
2013-05-17 Indefinite  
225-14-023 Promoting scientific progress, furthering public policy efforts, and translating innovation and discoveries into practice in the areas of medical and biological engineering. American Institute for Medical and Biological Engineering AIMBE CDRH
Anindita Saha
(301) 796-2537
2014-10-3 2019-10-2  
225-15-010 Sets forth principles and guidelines by which the parties intend to engage in a cooperative public education program. It is the parties’ intent to promote and increase the use of health knowledge, skills, and practices by the general population in its patterns of daily living. The National Forum for Heart Disease and Stroke Prevention OEA/OC
Helene Clayton-Jeter
(301) 796-8452
2015-03-29 2020-3-28  
225-15-012 Engage in sharing of pre-decisional nonpublic compliance and enforcement policy information is intended to improve Federal-State uniformity, cooperative regulatory activities, or implementation of Federal-State agreements. National Association of Attorneys General CTP
Ann Simoneau
(301) 796-9295
2015-05-29 Indefinite  
225-15-017 Promoting scientific progress through the exchange of scientific capital to develop innovative, collaborative projects in research, education, and outreach for the purpose of fostering medical product innovation, enabling the acceleration of medical product development, manufacturing, and translational therapeutics, and enhancing medical product safety.  Replaces MOU 225-05-8000. Critical Path Institute CDER
ShaAvheree Buckman-Garner
(301) 796-2600
2015-04-09 Indefinite  
225-16-026 Shared interests in promoting scientific progress through exchange of scientific capital in cardio-vascular education, training, and research. Inova Heart and Vascular Institute Anindita Saha, CDRH
301-796-2537
2015-11-01 2021-10-31  
225-16-025 Provide and promote FDA information in the form of FDA health consumer information to consumers. Healheo360 Steve Morin
301-796-0161
2017-03-22 2022-03-21  
225-16-027 Share interest in scientific progress in the disciplines that directly and indirectly affect human and animal health and medicine. Society for Toxicology Office of the Chief Scientist 2016-12-06 2021-12-05  
225-17-001 Promoting progress in the application of computer modelling and simulation in healthcare through the exchange of knowledge, information, case studies and policy. The Avicenna Alliance for Predictive Medicine Pras Pathmanathan, Ph.D. 2017-05-30 2027-05-31 2023-10-13
225-17-003 Shared interest in facilitating the successful adoption of Unique Device Identifiers (UDIs) across the healthcare device ecosystem especially with regard to the initial capture of UDI in supply chain and clinical health information technology (IT) systems. Association of Healthcare Resource and Materials Management (AHRMM) CDRH Terry L. Reed
301-796-6130
2016-10-21 2021-10-20  
225-17-005 FDA and AMA will collaborate to develop and distribute educational and outreach information to physicians to help them diagnose, treat and report foodborne illnesses; and educate patients on preventing foodborne illness. American Medical Association CFSAN,
Sharmi Das
202-402-3786
2016-11-08 2019-11-07  
225-17-008 Partnership between FDA and FDAAA on future specific undertakings that are considered beneficial for both organizations and are directly related to FDA's mission. Replaces MOU 225-03-8004. Food and Drug Administration Alumni Association (FDAAA) Dayle Cristinzio and Beth Fritsch
Office of External Affairs
2016-12-02 2028-05-22 2023-05-23
225-17-019 Establishes a framework for collaboration to facilitate existing and new mutually agreed upon programs and activities and to carry out their common goal to improve public health by stimulating and fostering medical product innovation and enabling medical product development. Bill and Melinda Gates Foundation RADM Carmen Maher
Assistant Surgeon General
Acting Assistant Commissioner for Counterterrorism and Emerging Threats,
Acting Director, Office of Counterterrorism & Emerging Threats (OCET)
Carmen.Maher@fda.hhs.gov
2017-06-27 Indefinite  
225-17-020 This MOU establishes a cooperative relationship between the American Association of Veterinary State Boards (AAVSB) and the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA CVM), regarding the exchange of veterinarian licensure status and enforcement information. American Association of Veterinary State Boards CVM
Michael Murphy, DVM, JD, Ph.D.
Veterinary Medical Officer
Michael.murphy@fda.hhs.gov
2017-10-18 Indefinite  
225-17-022 Promote scientific progress in food sciences through exchange of scientific capital in analytical methods development and validation, as well as in educational initiatives. Independent Laboratories Institute Palmer A. Orlandi, RADM
301-796-6592
2017-08-10 2022-08-10  
225-17-027 Establishes a framework for this collaboration to promote shared interests, which can be pursued through areas of
innovative toxicity testing, regulatory science, education and training.

The American College of Toxicity (ACT)

Office of the Chief Scientist

RADM Denise Hinton, Acting Chief Scientist
301-796-4880

2018-04-11 2023-04-10  
225-17-029 Accessing information to aid in assessing whether a particular intended use of a proposed new animal drug product meets the definition of "minor use." Medical Management International, Inc. d.b.a. Banfield Pet Hospital CVM
AskCVM@fda.hhs.gov
(240) 402-7002
2019-02-27 Indefinite (Renewed Yearly)  
225-17-030 Provide training scientists in regulatory science and policy to foster a better understanding of FDA’s work in their post-fellowship employment. Contribute to a workforce that can advance the field of regulatory science and provide leadership in this area in policy organizations, industry, academia, or the government. Reagan-Udall Foundation Office of the Chief Scientist
Leslie Wheelock, MS, RN
301-706-8450
2017-10-08 Indefinite  
225-17-020 Exchange of veterinarian licensure status and enforcement information, including information from the AAVSB licensure and disciplinary database and publicly available untitled letters and warning letters and publicly available information regarding enforcement actions FDA CVM pursues against veterinarians. American Association of Veterinary State Boards Michael Murphy, DVM, JD, Ph.D.
230-402-6217
2017-10-18 Indefinite  

225-18-007

Share common goals, priorities, and interests in promoting awareness and understanding of gender medicine and the science of sex-based differences and through mutually beneficial exchange of information of significance to/for women’s health. Replaces MOU 225-14-8000. Karolinska Institutet and Stockholms Läns Landsting/Hälso-Och Sjukvårdsförvaltningen (Stockholm County Council/ Healthcare Administration) OWH
Pamela E. Scott, Ph.D.
(301) 796-9440
2018-02-02 2023-02-02  
225-18-008 Collaborate to promote scientific progress in innovation, patient education, drug safety communications, training, research, including risk evaluation and mitigation strategies (REMS), and adverse event reporting. National Organization for Rare Disorders Andrea Furia-Helms, OMPT
301-796-8455
2018-02-20 2021-02-20  
225-18-009 Collaboration to promote the inclusion of diverse women in clinical trials Society for Clinical Research Sites
 
Pamela Scott, Ph.D., OWH
301-796-0530
2018-03-05 2019-03-05  
225-18-011 The purpose of the collaboration is to improve the safety of the American public when using FDA-regulated medical products. This MOU establishes the terms for collaboration to promote these shared interests. American Society of Health-System Pharmacists Office of External Affairs
Lubna Merchant
(301) 796-5162
2018-04-26 2021-04-26  
225-18-012 Establishes the terms for collaboration to promote scientific progress through exchange of scientific capital in medication error prevention and medication safety including risk evaluation and mitigation strategies (REMS) and related implementation, MedWatch adverse event reporting, scientific education, training and research programs.  The American Pharmacist Association

CDER/OSE

2021-10-05 Indefinite  
225-18-20 Shared interest in promoting scientific progress in diverse disciplines that affect human and animal health and medicine.
 
Institute of Quantitative Systems Pharmacology CDER
Padmaja Mummaneni, PhD.
301-796-2027
2018-06-19 2023-06-19  
225-18-024 To have a shared interest in scientific progress in the diverse disciplines and indirectly affect human and animal health and medicine. The Parties also endorse scientific training for faculty and staff to foster a well-grounded foundation in interdisciplinary fields in which academia and government share mutual interest. St. Jude Children’s Research Hospital CDER,
Padmaja Mummaneni
2018-10-09 Indefinite  
225-18-028 Established to promote a shared interest to encourage the identification, mitigation, and prevention of cybersecurity threats to medical devices. Health Information Sharing & Analysis Center and MedISAO

CDRH
Suzanne B. Schwartz, M.D., M. B.A
301-796-6937

CDRH
Seth Carmody, Ph.D.
301-796-6944

2018-09-14 2023-09-14  
225-18-030 Established to promote a shared interest to encourage the identification, mitigation, and prevention of cybersecurity threats to medical devices. Health Information Sharing & Analysis Center and Sensato Critical Infrastructure ISAO

CDRH
Suzanne B. Schwartz, M.D., M. B.A
301-796-6937

CDRH
Seth Carmody, Ph.D.
301-796-6944

2018-09-30 2023-09-30  
225-19-004 This MOU provides a framework for coordination and collaboration to promote the best science and practices associated with food chemistry and regulatory science. American Chemical Society CFSAN
Allen Rudman, Ph.D.
Senior Advisor
Senior Science and Policy Staff
240-402-1400
2019-06-04 2024-06-04  
225-19-023 Promote shared interests in various science-based initiatives, outreach, training, fellowships/internships, research and scientific education to advance health equity. The Alliance of Multicultural Physicians [a collective of five national organizations - The Association of American Indian Physicians (AAIP), Association of Black Cardiologists (ABC), National Council of Asian Pacific Islander Physicians (NCAPIP), National Hispanic Medical Association (NHMA),
and National Medical Association (NMA)]

Office of Minority Health and Health Equity (OMHHE)
CDR Yvonne Santiago
(240) 753-5808

2019-07-24 Indefinite 2023-04-13
225-19-024 The purpose of the collaboration is to improve the safety of the American public when using FDA‐regulated medical products. National Council for Prescription Drug Programs CDER
Claudia Manzo, Director 
Office of Medication Error Prevention and Risk Management
Office of Surveillance and Epidemiology
Claudia.Manzo@fda.hhs.gov
2019-06-17 2025-01-31 2022-01-31
225-20-009 This MOU between FDA and the Foundation will expedite collaborative research and data collection efforts related to COVID-19.  Under this MOU, FDA and the Foundation will seek opportunities to participate in collaborative research related to COVID-19 data collection. Reagan-Udall Foundation for the FDA

Trudy Lilly/OC/Senior Policy Coordinator
trudy.lilly@fda.hhs.gov

2021-04-13 2022-04-13  
225-20-013

To establish the FDA-AACR Oncology Educational Fellowship, as well as other collaborative educational efforts, as appropriate. The FDA and AACR share interests in promoting scientific progress through exchange of scientific knowledge in oncology education, collaborative learning, and research. Both institutions foresee benefits from the mutual exchange of educational expertise in translational oncology drug development and regulatory policy.

American Association for Cancer Research Oncology Center of Excellence
Jennifer Gao
Associate Director for Education
10903 New Hampshire Ave, WO 22/2135
Silver Spring, MD 20993
Jennifer.gao@fda.hhs.gov
240-402-4683
2020-05-28 2025-05-28  
225-20-014 FDA and AMA will collaborate to develop and disseminate educational and outreach information to physicians on dietary supplements. American Medical Association

CFSAN
Sharmi Das
Director, Division of Education, Outreach, and Information
5001 Campus Drive
College Park, MD 20740
Sharmi.Das@fda.hhs.gov
240-402-3786

2020-05-27 2025-05-27  
225-21-004 FDA and the Truth Initiative will share research and scientific information to increase our understanding about e-cigarettes and new tobacco products to improve youth prevention campaign messages and cessation tools. Truth Initiative CTP Office of Health Communications and Education
Dr. Tesfa Alexander
Director, Division of Research and Evaluation
Tesfa.Alexander@fda.hhs.gov
301-796-7745
2020-11-01 2025-10-31  

Sub-Topic Paragraphs

Other Categories

Domestic MOUs

Agreements between FDA and other domestic government entities, including federal, state, and local agencies.

Academic MOUs

Agreements between FDA and academic institutions and organizations.


Back to Top